Clinical Endocrinology · 1981 · 32 citations · 10 references
MedicineEndocrinologyPharmacologyBiochemical PharmacologyEndocrine OncologyNeuropharmacologyDopaminergic PharmacologyEndocrine TumorsHormone SecretionNeuroendocrine TumorsPituitary HormonesPituitary TumorsAdrenocorticotropic Hormone-secreting AdenomasAdrenocorticotropic Hormone-secreting Pituitary TumorsBromocriptine TreatmentCorticotroph TumorsHaloperidol PharmacologyPituitary Adenoma EndocrinologyPituitary Tumor Hormone SecretionPulmonary Carcinoid Tumors
Bromocriptine (0.13-13 microM) significantly inhibited ACTH secretion in a dose-dependent manner when added to cell cultures of a human corticotrophic adenoma for 24 h. Haloperidol (13 microM), but not serotonin (13 microM), blocked this inhibition but had no significant effect when added alone. In addition, dopamine (10 microM) reduced ACTH secretion during a 4-h incubation, whereas serotonin (0.01-10 microM) was ineffective. An ectopic ACTH secreting lung carcinoid was non-responsive to doses of bromocriptine up to 13 microM. These results demonstrate a direct suppressive action of bromocriptine on a human pituitary corticotrophic adenoma through dopaminergic rather than serotoninergic mechanisms.
10
A Radioimmunoassay for Rat Plasma ACTH
Lesley Rees, David M. Cook, J. W. Kendall et al. · Endocrinology · 1971 · 427 citations
Steven W. J. Lamberts, Jan G.M. Klijn, M. de Quijada et al. · The Journal of Clinical Endocrinology & Metabolism · 1980 · 130 citations